Evidence map›Paper›PMID 34377885›Full record

ArticleJCO precision oncology2021

Making External Validation Valid for Molecular Classifier Development.

Yilin Wu, Huei-Chung Huang, Li-Xuan Qin

Abstract read
In one paragraph

Article in JCO precision oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Which decisions affect cohort distribution in COVID-19 data analytics?AMIA ... Annual Symposium proceedings. AMIA Symposium · 2024
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Yilin WuDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.
Huei-Chung HuangDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.
Li-Xuan QinDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Evaluation and Development of Statistical Methods for Data Harmonization in Molecular PrognosticationR21HG012124 · NHGRI · SLOAN-KETTERING INST CAN RESEARCH · PI QIN, LI-XUAN · 2021 to 2021
$496k
Statistical Evaluation and Selection of Normalization Methods for microRNA Sequencing Data in Cancer Biomarker StudiesR21CA214845 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI QIN, LI-XUAN · 2018 to 2019
$414k
NCI NIH HHS P30 CA008748NCI NIH HHS R21 CA214845NHGRI NIH HHS R21 HG012124
6 · The paper itself

Abstract

purposeAccurate assessment of a molecular classifier that guides patient care is of paramount importance in precision oncology. Recent years have seen an increasing use of external validation for such assessment. However, little is known about how it is affected by ubiquitous unwanted variations in test data because of disparate experimental handling and by the use of data normalization for alleviating such variations.

methodsIn this paper, we studied these issues using two microarray data sets for the same set of tumor samples and additional data simulated by resampling under various levels of signal-to-noise ratio and different designs for array-to-sample allocation.

resultsWe showed that (1) unwanted variations can lead to biased classifier assessment and (2) data normalization mitigates the bias to varying extents depending on the specific method used. In particular, frozen normalization methods for test data outperform their conventional forms in terms of both reducing the bias in accuracy estimation and increasing robustness to handling effects. We make available our benchmarking tool as an R package on GitHub for performing such evaluation on additional methods for normalization and classification.

conclusionOur findings thus highlight the importance of proper test-data normalization for valid assessment by external validation and call for caution on the choice of normalization method for molecular classifier development.

Indexed as

NeoplasmsAlgorithmsBiasGene Expression ProfilingHumansPrecision Medicine

Identifiers

PMID34377885
PMCPMC8345919

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.